Matteo Morotti
Overview
Explore the profile of Matteo Morotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Valenti G, Vitagliano A, Morotti M, Giorda G, Sopracordevole F, Sapia F, et al.
Eur J Obstet Gynecol Reprod Biol
. 2021 Dec;
269:3-15.
PMID: 34942555
Objective: This systematic review and meta-analysis aimed to summarise the available evidence on the pre- and intra-operative risk factors for anastomotic leakage (AL) after bowel resection and anastomosis for ovarian...
12.
Addley S, Morotti M, Pinelli C, Soleymani Majd H
Gynecol Oncol Rep
. 2021 Aug;
37:100807.
PMID: 34381861
Surgery in advanced ovarian malignancy is indicated when complete debulking can be achieved. In patients with disease above the diaphragm, achieving R0 can present a surgical challenge and bring into...
13.
Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E, et al.
Cell Rep
. 2021 Jul;
36(3):109412.
PMID: 34289354
In this study, we investigate mechanisms leading to inflammation and immunoreactivity in ovarian tumors with homologous recombination deficiency (HRD). BRCA1 loss is found to lead to transcriptional reprogramming in tumor...
14.
Sarivalasis A, Morotti M, Mulvey A, Imbimbo M, Coukos G
Ther Adv Med Oncol
. 2021 May;
13:17588359211008399.
PMID: 33995591
Epithelial ovarian cancer (EOC) is the most important cause of gynecological cancer-related mortality. Despite improvements in medical therapies, particularly with the incorporation of drugs targeting homologous recombination deficiency, EOC survival...
15.
Artibani M, Masuda K, Hu Z, Rauher P, Mallett G, Wietek N, et al.
JCI Insight
. 2021 May;
6(11).
PMID: 33945502
Similar to tumor-initiating cells (TICs), minimal residual disease (MRD) is capable of reinitiating tumors and causing recurrence. However, the molecular characteristics of solid tumor MRD cells and drivers of their...
16.
Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton J, Curbishley S, et al.
Br J Cancer
. 2021 Mar;
124(11):1759-1776.
PMID: 33782566
Cancer is a leading cause of death worldwide and, despite new targeted therapies and immunotherapies, many patients with advanced-stage- or high-risk cancers still die, owing to metastatic disease. Adoptive T-cell...
17.
Gonzalez L, Rota I, Artibani M, Morotti M, Hu Z, Wietek N, et al.
Front Cell Dev Biol
. 2021 Mar;
9:605301.
PMID: 33763415
The conduits of life; the animal oviducts and human fallopian tubes are of paramount importance for reproduction in amniotes. They connect the ovary with the uterus and are essential for...
18.
Demetriou P, Abu-Shah E, Valvo S, McCuaig S, Mayya V, Kvalvaag A, et al.
Nat Immunol
. 2020 Oct;
22(1):99.
PMID: 33122852
No abstract available.
19.
Morotti M, Soleymani Majd H, Casarin J, Alazzam M, Damato S
Minerva Med
. 2020 Oct;
112(1):20-30.
PMID: 33104303
High-grade endometrial cancers (ECs) are an aggressive subset of ECs accounting for 70-80% of EC-related deaths. Currently, staging surgery, together with chemotherapy or radiotherapy, is the primary treatment strategy for...
20.
Morotti M, Zois C, El-Ansari R, Craze M, Rakha E, Fan S, et al.
Br J Cancer
. 2020 Oct;
124(2):494-505.
PMID: 33028955
Background: Glutamine (Gln) is an abundant nutrient used by cancer cells. Breast cancers cells and particularly triple-receptor negative breast cancer (TNBC) are reported to be dependent on Gln to produce...